BST2 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
endothelial cell	39 studies	54% ± 24%	Explore
natural killer cell	37 studies	44% ± 14%	Explore
macrophage	36 studies	48% ± 15%	Explore
B cell	34 studies	29% ± 12%	Explore
CD8-positive, alpha-beta T cell	30 studies	34% ± 16%	Explore
fibroblast	28 studies	40% ± 18%	Explore
conventional dendritic cell	27 studies	50% ± 16%	Explore
CD4-positive, alpha-beta T cell	26 studies	28% ± 12%	Explore
classical monocyte	25 studies	42% ± 16%	Explore
T cell	24 studies	29% ± 10%	Explore
non-classical monocyte	23 studies	51% ± 16%	Explore
pericyte	22 studies	40% ± 17%	Explore
regulatory T cell	22 studies	36% ± 15%	Explore
mast cell	20 studies	47% ± 11%	Explore
plasma cell	20 studies	46% ± 18%	Explore
plasmacytoid dendritic cell	20 studies	54% ± 19%	Explore
dendritic cell	19 studies	47% ± 22%	Explore
monocyte	18 studies	42% ± 15%	Explore
mature NK T cell	18 studies	37% ± 12%	Explore
smooth muscle cell	17 studies	41% ± 18%	Explore
gamma-delta T cell	17 studies	35% ± 10%	Explore
memory B cell	16 studies	30% ± 9%	Explore
naive B cell	16 studies	29% ± 11%	Explore
capillary endothelial cell	16 studies	56% ± 20%	Explore
CD16-negative, CD56-bright natural killer cell, human	15 studies	48% ± 16%	Explore
CD16-positive, CD56-dim natural killer cell, human	15 studies	46% ± 14%	Explore
endothelial cell of artery	14 studies	63% ± 20%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	13 studies	24% ± 6%	Explore
vein endothelial cell	13 studies	47% ± 21%	Explore
endothelial cell of vascular tree	12 studies	59% ± 19%	Explore
myeloid cell	12 studies	44% ± 18%	Explore
plasmablast	11 studies	50% ± 22%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	11 studies	34% ± 10%	Explore
connective tissue cell	11 studies	51% ± 18%	Explore
innate lymphoid cell	10 studies	44% ± 16%	Explore
basal cell	10 studies	35% ± 17%	Explore
mucosal invariant T cell	10 studies	33% ± 7%	Explore
CD4-positive, alpha-beta memory T cell	9 studies	37% ± 16%	Explore
CD8-positive, alpha-beta memory T cell	9 studies	40% ± 15%	Explore
effector memory CD8-positive, alpha-beta T cell	9 studies	33% ± 12%	Explore
secretory cell	8 studies	26% ± 11%	Explore
leukocyte	8 studies	34% ± 9%	Explore
abnormal cell	8 studies	31% ± 7%	Explore
hematopoietic stem cell	8 studies	51% ± 20%	Explore
effector CD8-positive, alpha-beta T cell	7 studies	46% ± 22%	Explore
IgG plasma cell	7 studies	23% ± 13%	Explore
T follicular helper cell	7 studies	31% ± 10%	Explore
alveolar macrophage	6 studies	40% ± 10%	Explore
myofibroblast cell	6 studies	56% ± 25%	Explore
IgA plasma cell	6 studies	31% ± 12%	Explore
type I pneumocyte	5 studies	25% ± 7%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	5 studies	31% ± 12%	Explore
hematopoietic precursor cell	5 studies	56% ± 28%	Explore
exhausted T cell	5 studies	52% ± 11%	Explore
mononuclear phagocyte	5 studies	53% ± 19%	Explore
epithelial cell	5 studies	42% ± 17%	Explore
immature B cell	5 studies	34% ± 13%	Explore
microglial cell	5 studies	47% ± 16%	Explore
effector CD4-positive, alpha-beta T cell	5 studies	52% ± 22%	Explore
intermediate monocyte	5 studies	55% ± 17%	Explore
effector memory CD4-positive, alpha-beta T cell	5 studies	37% ± 17%	Explore
club cell	4 studies	26% ± 7%	Explore
glomerular endothelial cell	4 studies	85% ± 5%	Explore
podocyte	4 studies	91% ± 5%	Explore
precursor B cell	4 studies	29% ± 9%	Explore
pro-B cell	4 studies	23% ± 3%	Explore
CD4-positive helper T cell	4 studies	20% ± 5%	Explore
luminal hormone-sensing cell of mammary gland	4 studies	32% ± 9%	Explore
group 3 innate lymphoid cell	4 studies	62% ± 11%	Explore
T-helper 17 cell	4 studies	40% ± 18%	Explore
CD4-positive, alpha-beta cytotoxic T cell	3 studies	42% ± 23%	Explore
central memory CD8-positive, alpha-beta T cell	3 studies	30% ± 13%	Explore
respiratory goblet cell	3 studies	33% ± 13%	Explore
monocyte-derived dendritic cell	3 studies	45% ± 17%	Explore
mesothelial cell	3 studies	52% ± 2%	Explore
common myeloid progenitor	3 studies	48% ± 33%	Explore
adventitial cell	3 studies	26% ± 5%	Explore
intraepithelial lymphocyte	3 studies	35% ± 10%	Explore
endothelial cell of sinusoid	3 studies	57% ± 28%	Explore
germinal center B cell	3 studies	29% ± 3%	Explore
inflammatory macrophage	3 studies	28% ± 11%	Explore
granulocyte	3 studies	48% ± 13%	Explore
T-helper 1 cell	3 studies	47% ± 17%	Explore
double negative thymocyte	3 studies	46% ± 13%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	19 studies	36% ± 13%	Explore
lung	13 studies	32% ± 8%	Explore
intestine	8 studies	32% ± 14%	Explore
kidney	6 studies	36% ± 13%	Explore
placenta	5 studies	27% ± 9%	Explore
lymph node	5 studies	37% ± 22%	Explore
liver	5 studies	27% ± 7%	Explore
bone marrow	4 studies	23% ± 9%	Explore
uterus	4 studies	45% ± 14%	Explore
breast	4 studies	33% ± 8%	Explore
adrenal gland	3 studies	29% ± 7%	Explore
brain	3 studies	35% ± 13%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
ovary	100%	28229.14	180 / 180	93%	1252.95	398 / 430
uterus	98%	3894.02	167 / 170	90%	892.89	412 / 459
breast	100%	6511.38	459 / 459	87%	741.27	972 / 1118
liver	100%	5105.61	226 / 226	81%	437.06	328 / 406
lung	100%	6085.21	577 / 578	75%	369.16	867 / 1155
kidney	100%	6333.24	89 / 89	66%	302.77	591 / 901
adrenal gland	100%	20998.70	258 / 258	58%	510.00	134 / 230
intestine	99%	3846.60	952 / 966	57%	259.48	303 / 527
esophagus	84%	2151.01	1218 / 1445	68%	296.14	125 / 183
bladder	81%	2403.05	17 / 21	69%	487.95	350 / 504
stomach	76%	3056.19	272 / 359	64%	240.00	182 / 286
prostate	100%	3981.16	244 / 245	36%	116.53	179 / 502
thymus	96%	2474.82	629 / 653	38%	208.06	229 / 605
skin	36%	508.93	650 / 1809	81%	586.27	381 / 472
pancreas	21%	299.52	69 / 328	89%	501.65	158 / 178
brain	65%	1201.34	1726 / 2642	44%	168.05	313 / 705
lymph node	0%	0	0 / 0	100%	800.85	29 / 29
spleen	100%	10096.22	241 / 241	0%	0	0 / 0
adipose	100%	7688.51	1203 / 1204	0%	0	0 / 0
tonsil	0%	0	0 / 0	98%	771.89	44 / 45
peripheral blood	97%	6152.69	902 / 929	0%	0	0 / 0
heart	95%	2121.36	822 / 861	0%	0	0 / 0
blood vessel	76%	2291.55	1011 / 1335	0%	0	0 / 0
muscle	52%	679.66	421 / 803	0%	0	0 / 0
eye	0%	0	0 / 0	21%	103.94	17 / 80
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0002737	Biological process	negative regulation of plasmacytoid dendritic cell cytokine production
GO_0045071	Biological process	negative regulation of viral genome replication
GO_0045087	Biological process	innate immune response
GO_0009615	Biological process	response to virus
GO_0051607	Biological process	defense response to virus
GO_0035455	Biological process	response to interferon-alpha
GO_0034341	Biological process	response to type II interferon
GO_0043123	Biological process	positive regulation of canonical NF-kappaB signal transduction
GO_0042113	Biological process	B cell activation
GO_1901253	Biological process	negative regulation of intracellular transport of viral material
GO_0030336	Biological process	negative regulation of cell migration
GO_0035456	Biological process	response to interferon-beta
GO_0032956	Biological process	regulation of actin cytoskeleton organization
GO_0070665	Biological process	positive regulation of leukocyte proliferation
GO_0030308	Biological process	negative regulation of cell growth
GO_0016324	Cellular component	apical plasma membrane
GO_0005886	Cellular component	plasma membrane
GO_0045121	Cellular component	membrane raft
GO_0016020	Cellular component	membrane
GO_0035577	Cellular component	azurophil granule membrane
GO_0070062	Cellular component	extracellular exosome
GO_0005794	Cellular component	Golgi apparatus
GO_0009986	Cellular component	cell surface
GO_0005771	Cellular component	multivesicular body
GO_0005737	Cellular component	cytoplasm
GO_0043231	Cellular component	intracellular membrane-bounded organelle
GO_0098552	Cellular component	side of membrane
GO_0042803	Molecular function	protein homodimerization activity
GO_0042802	Molecular function	identical protein binding
GO_0008191	Molecular function	metalloendopeptidase inhibitor activity
GO_0003723	Molecular function	RNA binding
GO_0005515	Molecular function	protein binding

IV. Literature review

[source]

Gene name	BST2
Protein name	Bone marrow stromal antigen 2 Bone marrow stromal antigen 2 (BST-2) (HM1.24 antigen) (Tetherin) (CD antigen CD317) Bone marrow stromal cell antigen 2
Synonyms	CD317
Description	FUNCTION: IFN-induced antiviral host restriction factor which efficiently blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. Acts as a direct physical tether, holding virions to the cell membrane and linking virions to each other. The tethered virions can be internalized by endocytosis and subsequently degraded or they can remain on the cell surface. In either case, their spread as cell-free virions is restricted . Its target viruses belong to diverse families, including retroviridae: human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), simian immunodeficiency viruses (SIVs), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), prototype foamy virus (PFV), Mason-Pfizer monkey virus (MPMV), human T-cell leukemia virus type 1 (HTLV-1), Rous sarcoma virus (RSV) and murine leukemia virus (MLV), flavivirideae: hepatitis C virus (HCV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), arenaviridae: lassa virus (LASV) and machupo virus (MACV), herpesviridae: kaposis sarcoma-associated herpesvirus (KSHV), rhabdoviridae: vesicular stomatitis virus (VSV), orthomyxoviridae: influenza A virus, paramyxoviridae: nipah virus, and coronaviridae: SARS-CoV . Can inhibit cell surface proteolytic activity of MMP14 causing decreased activation of MMP15 which results in inhibition of cell growth and migration . Can stimulate signaling by LILRA4/ILT7 and consequently provide negative feedback to the production of IFN by plasmacytoid dendritic cells in response to viral infection . Plays a role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. Isoform 1 and isoform 2 are both effective viral restriction factors but have differing antiviral and signaling activities . Isoform 2 is resistant to HIV-1 Vpu-mediated degradation and restricts HIV-1 viral budding in the presence of Vpu . Isoform 1 acts as an activator of NF-kappa-B and this activity is inhibited by isoform 2 . .
Accessions	ENST00000252593.7 [Q10589-1] A0A024R7H5 Q10589 A0A7P0T9F9 ENST00000527220.2

BST2 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review